Your browser doesn't support javascript.
loading
Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology.
Inwald, E C; Ortmann, O; Koller, M; Zeman, F; Hofstädter, F; Evert, M; Brockhoff, G; Klinkhammer-Schalke, M.
  • Inwald EC; Department of Gynecology and Obstetrics, University Medical Center Regensburg, Regensburg, Germany. elisabeth.inwald@klinik.uni-regensburg.de.
  • Ortmann O; Department of Gynecology and Obstetrics, University Medical Center Regensburg, Regensburg, Germany.
  • Koller M; Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany.
  • Zeman F; Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany.
  • Hofstädter F; Tumor Center Regensburg, University of Regensburg, Regensburg, Germany.
  • Evert M; Institute of Pathology, University of Regensburg, Regensburg, Germany.
  • Brockhoff G; Department of Gynecology and Obstetrics, University Medical Center Regensburg, Regensburg, Germany.
  • Klinkhammer-Schalke M; Tumor Center Regensburg, University of Regensburg, Regensburg, Germany.
Breast Cancer Res Treat ; 163(1): 119-130, 2017 May.
Article en En | MEDLINE | ID: mdl-28205042
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptor ErbB-2 Tipo de estudio: Diagnostic_studies / Prognostic_studies / Screening_studies Límite: Aged / Aged80 / Female / Humans / Middle aged País como asunto: Europa Idioma: En Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptor ErbB-2 Tipo de estudio: Diagnostic_studies / Prognostic_studies / Screening_studies Límite: Aged / Aged80 / Female / Humans / Middle aged País como asunto: Europa Idioma: En Año: 2017 Tipo del documento: Article